UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(MARK ONE)
☒ QUARTERLY REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarter ended June 30, 2023
☐ TRANSITION REPORT PURSUANT TO SECTION
13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission file number: 001-40723
ABRI SPAC I, INC. |
(Exact Name of Registrant as Specified in Its Charter) |
|
Delaware | | 86-2861807 |
(State or other jurisdiction of
incorporation or organization) | | (I.R.S. Employer
Identification No.) |
9663 Santa Monica Blvd., No. 1091 Beverly Hills, CA 90210 |
(Address of principal executive offices)
(424) 732-1021
(Issuer’s telephone number)
Check whether the issuer (1) filed all reports
required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ No ☒
Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒
No ☐
Indicate by check mark whether the Registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.
See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company”
and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ |
Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging Growth Company | ☒ |
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☒ No ☐
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Units, each consisting of one share of Common Stock and one Redeemable Warrant | | ASPAU | | Nasdaq Capital Market |
| | | | |
Common Stock, par value $0.0001 per share | | ASPA | | Nasdaq Capital Market |
| | | | |
Warrants, each exercisable for one share of Common Stock for $11.50 per share | | ASPAW | | Nasdaq Capital Market |
As of August 14, 2023, 2,410,226 shares
of common stock, $0.0001 par value, were issued and outstanding.
ABRI SPAC I, INC.
FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2023
TABLE OF CONTENTS
PART I – FINANCIAL INFORMATION
ITEM 1. Unaudited Financial Statements
ABRI SPAC I, INC.
CONDENSED BALANCE SHEETS
| |
June 30, 2023 | | |
December 31, 2022 | |
| |
| | |
| |
ASSETS | |
| | |
| |
Current assets: | |
| | |
| |
Cash | |
$ | 148,389 | | |
$ | 381,293 | |
Prepaid expenses and other current assets | |
| 115,967 | | |
| 252,463 | |
Total current assets | |
| 264,356 | | |
| 633,756 | |
| |
| | | |
| | |
Marketable securities held in Trust Account, at fair value | |
| 13,650,778 | | |
| 12,841,399 | |
Total assets | |
$ | 13,915,134 | | |
$ | 13,475,155 | |
| |
| | | |
| | |
LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ DEFICIT | |
| | | |
| | |
Current liabilities: | |
| | | |
| | |
Accounts payable and accrued expenses | |
$ | 432,649 | | |
$ | 441,739 | |
Accrued legal fees | |
| 2,575,551 | | |
| 2,113,078 | |
Total current liabilities | |
| 3,008,200 | | |
| 2,554,817 | |
Promissory notes, related party | |
| 1,584,284 | | |
| 1,146,784 | |
Convertible promissory notes, related party | |
| 1,650,000 | | |
| 1,250,000 | |
Warrant liabilities, at fair value | |
| 10,311 | | |
| 17,676 | |
Deferred underwriting commissions | |
| 1,500,000 | | |
| 1,500,000 | |
Total liabilities | |
| 7,752,795 | | |
| 6,469,277 | |
| |
| | | |
| | |
Commitments and Contingencies (Note 4) | |
| | | |
| | |
| |
| | | |
| | |
Common stock subject to possible redemption, par value $0.0001, 100,000,000 shares authorized; 1,252,372 shares outstanding as of June 30, 2023 and December 31, 2022 | |
| 13,450,571 | | |
| 12,841,399 | |
Stockholders’ deficit: | |
| | | |
| | |
Preferred stock, par value $0.0001, 1,000,000 shares authorized, none issued and outstanding | |
| - | | |
| - | |
Common stock, par value $0.0001, 100,000,000 shares authorized; 1,728,078 shares issued and outstanding | |
| 173 | | |
| 173 | |
Additional paid-in capital | |
| - | | |
| - | |
Accumulated deficit | |
| (7,288,405 | ) | |
| (5,835,694 | ) |
Total stockholders’ deficit | |
| (7,288,232 | ) | |
| (5,835,521 | ) |
Total liabilities, redeemable common stock and stockholders’ deficit | |
$ | 13,915,134 | | |
$ | 13,475,155 | |
The accompanying footnotes are an integral part
of these unaudited condensed financial statements.
ABRI SPAC I, INC.
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)
| |
For the
Three Months
Ended | | |
For the
Three Months
Ended | | |
For the
Six Months
Ended | | |
For the
Six Months
Ended | |
| |
June 30,
2023 | | |
June 30,
2022 | | |
June 30,
2023 | | |
June 30,
2022 | |
| |
| | |
| | |
| | |
| |
Operating expenses: | |
| | |
| | |
| | |
| |
Professional fees | |
$ | 341,146 | | |
$ | 307,154 | | |
$ | 761,279 | | |
$ | 1,401,354 | |
Selling, general and administrative | |
| 186,903 | | |
| 197,451 | | |
| 344,626 | | |
| 498,960 | |
Total operating expenses | |
| 528,049 | | |
| 504,605 | | |
| 1,105,905 | | |
| 1,900,314 | |
| |
| | | |
| | | |
| | | |
| | |
Loss from operations | |
| (528,049 | ) | |
| (504,605 | ) | |
| (1,105,905 | ) | |
| (1,900,314 | ) |
| |
| | | |
| | | |
| | | |
| | |
Other income: | |
| | | |
| | | |
| | | |
| | |
Interest income | |
| 160,991 | | |
| 76,629 | | |
| 303,001 | | |
| 81,973 | |
Change in fair value of warrant liabilities | |
| 16,203 | | |
| 41,244 | | |
| 7,365 | | |
| 109,002 | |
| |
| 177,194 | | |
| 117,873 | | |
| 310,366 | | |
| 190,975 | |
| |
| | | |
| | | |
| | | |
| | |
Loss before income taxes | |
| (350,855 | ) | |
| (386,732 | ) | |
| (795,539 | ) | |
| (1,709,339 | ) |
Provision for income taxes | |
| (24,000 | ) | |
| - | | |
| (48,000 | ) | |
| - | |
| |
| | | |
| | | |
| | | |
| | |
Net loss | |
$ | (374,855 | ) | |
$ | (386,732 | ) | |
$ | (843,539 | ) | |
$ | (1,709,339 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted-average common shares outstanding, basic and diluted, redeemable shares subject to redemption | |
| 1,252,372 | | |
| 5,733,920 | | |
| 1,252,372 | | |
| 5,733,920 | |
Basic and diluted net income (loss) per share, redeemable shares subject
to redemption | |
$ | 0.01 | | |
$ | - | | |
$ | (0.00 | ) | |
$ | (0.14 | ) |
| |
| | | |
| | | |
| | | |
| | |
Weighted-average common shares outstanding, basic and diluted, non-redeemable shares | |
| 1,728,078 | | |
| 1,728,078 | | |
| 1,728,078 | | |
| 1,728,078 | |
Basic and diluted net loss per share, non-redeemable shares | |
$ | (0.23 | ) | |
$ | (0.21 | ) | |
$ | (0.49 | ) | |
$ | (0.54 | ) |
The accompanying footnotes are an integral part
of these unaudited condensed financial statements.
ABRI SPAC I, INC.
CONDENSED STATEMENTS OF CHANGE IN STOCKHOLDERS’
EQUITY (DEFICIT)
AND REDEEMABLE COMMON STOCK
(Unaudited)
| |
Common Stock Subject to | | |
| | |
| | |
Additional | | |
| | |
Total | |
| |
Possible Redemption | | |
Common Stock | | |
Paid-in | | |
Accumulated | | |
Stockholder’s | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Equity (Deficit) | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance, January 1, 2023 | |
| 1,252,372 | | |
$ | 12,841,399 | | |
| 1,728,078 | | |
$ | 173 | | |
$ | - | | |
$ | (5,835,694 | ) | |
$ | (5,835,521 | ) |
Accretion of common stock to redemption value | |
| - | | |
| 307,596 | | |
| - | | |
| - | | |
| - | | |
| (307,596 | ) | |
| (307,596 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (468,684 | ) | |
| (468,684 | ) |
Balance at March 31, 2023 | |
| 1,252,372 | | |
$ | 13,148,995 | | |
| 1,728,078 | | |
$ | 173 | | |
| - | | |
$ | (6,611,974 | ) | |
$ | (6,611,801 | ) |
Accretion of common stock to redemption value | |
| - | | |
| 301,576 | | |
| - | | |
| - | | |
| - | | |
| (301,576 | ) | |
| (301,576 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (374,855 | ) | |
| (374,855 | ) |
Balance at June 30, 2023 | |
| 1,252,372 | | |
$ | 13,450,571 | | |
| 1,728,078 | | |
$ | 173 | | |
| - | | |
$ | (7,288,405 | ) | |
$ | (7,288,232 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
| |
Common Stock Subject to | | |
| | |
| | |
Additional | | |
| | |
Total | |
| |
Possible Redemption | | |
Common Stock | | |
Paid-in | | |
Accumulated | | |
Stockholder’s | |
| |
Shares | | |
Amount | | |
Shares | | |
Amount | | |
Capital | | |
Deficit | | |
Equity (Deficit) | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance at January 1, 2022 | |
| 5,733,920 | | |
$ | 52,323,289 | | |
| 1,728,078 | | |
$ | 173 | | |
$ | 4,262,491 | | |
$ | (1,127,612 | ) | |
$ | 3,135,052 | |
Accretion of common stock to redemption value | |
| - | | |
| 1,099,501 | | |
| - | | |
| - | | |
| (1,094,157 | ) | |
| (5,344 | ) | |
| (1,099,501 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (1,322,607 | ) | |
| (1,322,607 | ) |
Balance at March 31, 2022 | |
| 5,733,920 | | |
$ | 53,422,790 | | |
| 1,728,078 | | |
$ | 173 | | |
$ | 3,168,334 | | |
$ | (2,455,563 | ) | |
$ | 712,944 | |
Accretion of common stock to redemption value | |
| - | | |
| 1,195,374 | | |
| - | | |
| - | | |
| (1,118,745 | ) | |
| (76,629 | ) | |
| (1,195,374 | ) |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (386,732 | ) | |
| (386,732 | ) |
Balance at June 30, 2022 | |
| 5,733,920 | | |
$ | 54,618,164 | | |
| 1,728,078 | | |
$ | 173 | | |
$ | 2,049,589 | | |
$ | (2,918,924 | ) | |
$ | (869,162 | ) |
The accompanying footnotes are an integral part
of these unaudited condensed financial statements.
ABRI SPAC I, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
| |
For the
Six Months
Ended | | |
For the
Six Months
Ended | |
| |
June 30,
2023 | | |
June 30,
2022 | |
| |
| | |
| |
CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | |
| |
Net loss | |
$ | (843,539 | ) | |
$ | (1,709,339 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Change in fair value of warrant liabilities | |
| (7,365 | ) | |
| (109,002 | ) |
Interest earned on marketable securities held in Trust Account | |
| - | | |
| (81,973 | ) |
Changes in operating assets and liabilities: | |
| | | |
| | |
Prepaid expenses and other current assets | |
| 136,496 | | |
| 72,868 | |
Accounts payable and accrued expenses | |
| 453,383 | | |
| 1,029,259 | |
Net cash used in operating activities | |
| (261,025 | ) | |
| (798,187 | ) |
| |
| | | |
| | |
CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | |
Investments in marketable securities held in Trust Account | |
| (809,379 | ) | |
| - | |
Net cash used in investing activities | |
| (809,379 | ) | |
| - | |
| |
| | | |
| | |
CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | |
Proceeds from convertible promissory notes, related party | |
| 400,000 | | |
| - | |
Proceeds of notes payable - related party | |
| 437,500 | | |
| 800,000 | |
Net cash provided by financing activities | |
| 837,500 | | |
| 800,000 | |
| |
| | | |
| | |
NET CHANGE IN CASH | |
| (232,904 | ) | |
| 1,813 | |
Cash - Beginning of period | |
| 381,293 | | |
| 154,942 | |
Cash - End of period | |
$ | 148,389 | | |
$ | 156,755 | |
| |
| | | |
| | |
SUPPLEMENTAL CASH FLOW INFORMATION: | |
| | | |
| | |
Non-cash investing and financing activities: | |
| | | |
| | |
Accretion of common stock to redemption value | |
$ | 609,172 | | |
$ | 2,294,875 | |
The accompanying footnotes are an integral part
of these unaudited condensed financial statements.
ABRI SPAC I, INC.
NOTES TO UNAUDITED FINANCIAL STATEMENTS
FOR THE THREE AND SIX MONTHS ENDED JUNE 30,
2023
(Unaudited)
NOTE 1 — NATURE OF THE ORGANIZATION AND
BUSINESS
Abri SPAC I, Inc (“Abri”
or the “Company”) was incorporated in the State of Delaware on March 18, 2021. The Company’s business purpose is to
effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or
more businesses (our “Initial Business Combination”). Throughout this report, the terms “our,” “we,”
“us,” and the “Company” refer to Abri SPAC I, Inc.
As of June 30, 2023, and the
date of this filing, the Company had not commenced core operations. All activity for the period
from March 18, 2021 (inception) through June 30, 2023 related to organizational activities, those necessary to consummate the initial
public offering (“IPO”) and identify a target company for a business combination. The Company will not generate any
operating revenues until after the completion of the Initial Business Combination, at the earliest.
The Company generates non-operating income in the form of interest income and gains from the marketable securities held in the Trust Account,
and gains or losses from the change in fair value of the warrant liabilities.
The registration statement
pursuant to which the Company registered its securities offered in the IPO was declared effective on August 9, 2021. On August 12, 2021,
the Company consummated its IPO of 5,000,000 units (each, a “Unit” and collectively, the “Units”), at
$10.00 per Unit, generating gross proceeds of $50,000,000 and incurring offering costs of $973,988. The Company granted the
underwriter a 45-day option to purchase up to an additional 750,000 Units at the IPO price to cover over-allotments.
Simultaneously with the consummation
of the closing of the Initial Public Offering, the Company completed the private sale of 276,250 units (the “Private Units”)
to Abri Ventures I, LLC (“Abri Ventures”), the Company’s sponsor (the “Sponsor”) at a purchase price of
$10.00 per Private Unit, generating gross proceeds to the Company of $2,762,500.
Following the closing of the
IPO on August 12, 2021, an amount of $50,000,000 net proceeds from the IPO and sale of the Private Units was placed in a trust account
in the United States maintained by Continental Stock Transfer & Trust Company, as trustee (the “Trust Account”). The funds
held in the Trust Account were invested only in U.S. government securities with a maturity of 185 days or less or in money market
funds meeting certain conditions under Rule 2a-7 under the Investment Company Act which invest only in direct U.S. government treasury
obligations so that we are not deemed to be an investment company under the Investment Company Act. Except with respect to interest earned
on the funds held in the Trust Account, the Trust Account is intended as a holding place for funds pending the earliest to occur of: (i)
the completion of the Initial Business Combination; (ii) the redemption of any public shares properly submitted in connection with a stockholder
vote to amend the Company’s amended and restated certificate of incorporation (A) to modify the substance or timing of the Company’s
obligation to redeem 100% of the public shares if the Company does not complete the initial Business Combination within 12 months
from the closing of the IPO (or up to 18 months from the closing of this offering with the mandatory extensions of the period of time
to consummate an Initial Business Combination) or (B) with respect to any other provision relating to stockholders’ rights or pre-Initial
Business Combination activity; or (iii) absent an Initial Business Combination within 12 months from the closing of the IPO (or up to
18 months from the closing of this offering with the mandatory extensions of the period of time to consummate an Initial Business Combination),
the return of the funds held in the Trust Account to the public stockholders as part of redemption of the public shares. The Company’s
amended and restated certificate of incorporation has been further amended by stockholders to extend the time in which the Company has
to complete an Initial Business Combination to February 12, 2024.
On August 19, 2021, the underwriters
notified the Company of their intent to exercise of the over-allotment option in part and, on August 23, 2021, the underwriters purchased 733,920 additional
Units (the “Additional Units”) at $10.00 per Additional Unit upon the closing of the over-allotment option, generating
additional gross proceeds of $7,339,200. On August 23, 2021, simultaneously with the sale of the Additional Units, the Company consummated
the sale of an additional 18,348 Private Units at $10.00 per additional Private Unit (the “Additional Private Units”),
generating additional gross proceeds of $183,480. A total of $7,339,200 of the net proceeds from the sale of the Additional Units
and the Additional Private Units was deposited in the Trust Account, bringing the aggregate proceeds held in the Trust Account on that
date to $57,339,200.
The stock exchange listing
rules provide that the Initial Business Combination must be with one or more target businesses that together have a fair market value
equal to at least 80% of the value of the assets held in the Trust Account (as defined below) (excluding the deferred underwriting
commissions and taxes payable) at the time of the Company signing a definitive agreement in connection with the Initial Business Combination.
The Company will only complete an Initial Business Combination if the post-Initial Business Combination company owns or acquires 50%
or more of the outstanding voting securities of the target or otherwise acquires a controlling interest in the target sufficient for it
not to be required to register as an investment company under the Investment Company Act of 1940, as amended (the “Investment Company
Act”). There is no assurance that the Company will be able to successfully effect an Initial Business Combination.
The payment to the Company’s
Sponsor of a monthly fee of $10,000 is for general and administrative services including office space, utilities and secretarial
support, which the Company records as operating expense on its statements of operations. However, pursuant to the terms of such agreement,
the Company may delay payment of such monthly fee upon a determination by the audit committee that the Company lacks sufficient funds
held outside the trust to pay actual or anticipated expenses in connection with the Initial Business Combination. Any such unpaid amount
will accrue without interest and be due and payable no later than the date of the consummation of the Initial Business Combination. This
arrangement is being agreed to by its Sponsor for the Company’s benefit. Management believes that the fee charged by the Sponsor
is at least as favorable as what could have been obtained from an unaffiliated person. This arrangement will terminate upon completion
of the Initial Business Combination or the distribution of the Trust Account to the public stockholders. Other than the $10,000 per
month fee, no compensation of any kind (including finder’s fees, consulting fees or other similar compensation) will be paid to
insiders, members of the management team or any of their respective affiliates, for services rendered prior to or in connection with the
consummation of the Initial Business Combination (regardless of the type of transaction that it is). However, such individuals will receive
reimbursement for any out-of-pocket expenses incurred by them in connection with activities on the Company’s behalf, such as identifying
potential target businesses, performing business due diligence on suitable target businesses and business combinations, as well as traveling
to and from the offices, plants or similar locations of prospective target businesses to examine their operations. Since the role of present
management after the Initial Business Combination is uncertain, the Company has no ability to determine what remuneration, if any, will
be paid to those persons after the Initial Business Combination.
The funds outside of the Trust
Account are for working capital requirements in searching for an Initial Business Combination. The allocation such funds represents the
Company’s best estimate of the intended uses of these funds. If the estimate of the costs of undertaking due diligence and negotiating
our Initial Business Combination is less than the actual amount necessary to do so, the Company may be required to raise additional capital,
the amount, availability and cost of which is currently unascertainable. In this event, the Company could seek such additional capital
through loans or additional investments from insiders, members of management team or third parties, but the insiders, members of the Company’s
management team or third parties are not under any obligation to advance funds to, or invest in the Company.
The Company will likely use
substantially all of the net proceeds of this offering, including the funds held in the Trust Account, in connection with the Initial
Business Combination and to pay expenses relating thereto, including the deferred underwriting commissions payable to the underwriter
in an amount equal to 3.0% of the total gross proceeds raised in the offering upon consummation of the Initial Business Combination.
To the extent that the Company’s capital stock is used in whole or in part as consideration to effect the Initial Business Combination,
the proceeds held in the Trust Account which are not used to consummate an Initial Business Combination will be disbursed to the combined
company and will, along with any other net proceeds not expended, be used as working capital to finance the operations of the target business.
Such working capital funds could be used in a variety of ways, including continuing or expanding the target business’ operations,
for strategic acquisitions and for marketing, research and development of existing or new products.
To the extent the Company
is unable to consummate an Initial Business Combination, the Company will pay the costs of liquidation from the remaining assets outside
of the Trust Account. If such funds are insufficient, the Company’s insiders have agreed to pay the funds necessary to complete
such liquidation and have agreed not to seek repayment of such expenses.
The Company believes that
it will not have sufficient available funds to operate for up to the next 12 months, assuming that the Initial Business Combination is
not consummated during that time. However, if necessary, in order to meet the Company’s working capital needs following the consummation
of this offering, the insiders may, but are not obligated to, loan the Company funds, from time to time or at any time, in whatever amount
they deem reasonable in their sole discretion. Each loan would be evidenced by a promissory note. The notes would either be paid upon
consummation of the Initial Business Combination, without interest, or, at the lender’s discretion, up to $750,000 of the notes
may be converted upon consummation of our Initial Business Combination into additional Private Warrants at a price of $1.00 per warrant.
Notwithstanding, there is no guarantee that the Company will receive such funds. The Company’s stockholders have approved the issuance
of the Private Warrants upon conversion of such notes, to the extent the holder wishes to so convert such notes at the time of the consummation
of the Initial Business Combination. If the Company does not complete an Initial Business Combination, any loans and advances from the
insiders or their affiliates, will be repaid only from amounts remaining outside the Trust Account, if any.
The Company’s Sponsor,
officers and directors have entered into a letter agreement with the Company, pursuant to which they have agreed to waive their redemption
rights with respect to their insider shares and any public shares they may hold in connection with the completion of the Initial Business
Combination. In addition, the Sponsor and its officers and directors have agreed to waive their rights to liquidating distributions from
the Trust Account with respect to their insider shares if the Company fails to complete an Initial Business Combination within the prescribed
time frame. However, if its Sponsor or any of its officers, directors or affiliates acquire public shares in or after this offering, they
will be entitled to liquidating distributions from the Trust Account with respect to such public shares if the Company fails to complete
an Initial Business Combination within the prescribed time frame.
The Company will provide its
public stockholders with the opportunity to redeem all or a portion of their shares of common stock upon the completion of the Initial
Business Combination either (i) in connection with a stockholder meeting called to approve the Initial Business Combination or (ii) by
means of a tender offer. The decision as to whether the Company will seek stockholder approval of a proposed Initial Business Combination
or conduct a tender offer will be made by the Company, solely in the Company’s discretion. The public stockholders will be entitled
to redeem their shares at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account as of
two business days prior to the consummation of the Initial Business Combination including interest earned on the funds held in the Trust
Account and not previously released to the Company to pay its franchise and income taxes, divided by the number of then outstanding public
shares, subject to the limitations. As of June 30, 2023, the amount in the Trust Account is approximately $10.90 per public share.
The shares of common stock
subject to redemption was classified as temporary equity upon the completion of the IPO and will subsequently be accreted to redemption
value, in accordance with Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”)
480, Distinguishing Liabilities from Equity, (“ASC 480”). In such case, the Company will proceed with an Initial Business
Combination if the Company has net tangible assets of at least $5,000,001 upon such consummation of an Initial Business Combination
and, if the Company seeks stockholder approval, a majority of the issued and outstanding shares voted are voted in favor of the Initial
Business Combination.
The Company had 12 months
from the closing of the IPO (the “Combination Period”) on August 9, 2021 to complete the Initial Business Combination. On
August 5, 2022, pursuant to the Company’s certificate of incorporation and investment trust agreement, the Company deposited $573,392 into
the Trust Account to extend the time to complete its Initial Business Combination for an additional three months, or until November 12,
2022. On November 1, 2022, in connection with a second extension, Abri deposited $573,392 (or $0.10 for each share of common
stock issued in the IPO) into the Trust Account to extend the time to complete a business combination to February 12, 2023. The Company
further amended the certificate of incorporation and investment trust agreement, as described below. If the Company is unable to complete
its Initial Business Combination within the Combination Period, the Company will: (i) cease all operations except for the purpose of winding
up, (ii) as promptly as reasonably possible but not more than ten business days thereafter, redeem the public shares, at a per-share price,
payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the
Trust Account and not previously released to us to pay our taxes (less up to $100,000 of interest to pay dissolution expenses), divided
by the number of then outstanding public shares, which redemption will completely extinguish public stockholders’ rights as stockholders
(including the right to receive further liquidating distributions, if any), and (iii) as promptly as reasonably possible following such
redemption, subject to the approval of our remaining stockholders and the Company’s board of directors, liquidate and dissolve,
subject in each case to the Company’s obligations under Delaware law to provide for claims of creditors and the requirements of
other applicable law. There will be no redemption rights or liquidating distributions with respect to the warrants, which will expire
worthless if the Company fails to complete its Initial Business Combination prior to the mandatory liquidation date.
Trust Account Redemptions
On December 9, 2022, the Company
held a special meeting of stockholders at which such stockholders voted to amend the Company’s amended and restated certificate
of incorporation and its investment trust agreement, giving the Company the right to extend the date by which the Company must complete
its Initial Business Combination up to six times for an additional one month each time, from February 12, 2023 to August 12, 2023, by
depositing $87,500 into the Trust Account for each one-month extension. In connection with the special meeting, 4,481,548 shares
of common stock were tendered for redemption, resulting in redemption payments of $45,952,278 out of the Trust Account. On February
6, 2023, March 10, 2023, April 11, 2023, May 11, 2023, June 9, 2023 and July 10, 2023, Abri deposited $87,500 into the Trust Account for
each one-month extension (or a total of $525,000) to extend the time to complete a business combination to August 12, 2023, of which $437,500
had been deposited as of June 30, 2023. On August 7, 2023, the Company held a second special meeting of stockholders at which such stockholders
voted to amend the Company’s amended and restated certificate of incorporation and its investment trust agreement, giving the Company
the right to extend the date by which the Company must complete its Initial Business Combination from August 12, 2023 to February 12,
2024 with no additional payment to the Company’s trust account.
Risks and Uncertainties
Management continues to evaluate
the impact of the Russia-Ukraine war on the economy and the capital markets and has concluded that, while it is reasonably possible that
such events could have negative effects on the Company’s financial position, results of its operations, and/or search for a target
company, the specific impacts are not readily determinable as of the date of these financial statements. The financial statements do not
include any adjustments that might result from the outcome of these uncertainties.
Going Concern and Management Liquidity Plans
As of June 30, 2023, the Company had cash of $148,389 and working
capital deficiency of $2,743,844. The Company’s liquidity needs through the date of this filing have been satisfied through proceeds
from notes payable and advances from a related party and from the issuance of common stock. The liquidity needs consist of paying existing
accounts payable, identifying and evaluating prospective business combination candidates, performing due diligence on prospective target
businesses, paying for travel expenditures, selecting the target business to merge with or acquire, and structuring, negotiating and consummating
an Initial Business Combination. Although certain of the Company’s initial stockholders, officers and directors or their affiliates
have committed to loan the Company funds from time to time or at any time, in whatever amount they deem reasonable in their sole discretion,
there is no guarantee that the Company will continue to receive such funds.
Accordingly, the accompanying
financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S.
GAAP”), which contemplate continuation of the Company as a going concern and the realization of assets and the satisfaction of liabilities
in the normal course of business. These financial statements do not include any adjustments that might result from the outcome of this
uncertainty. Further, the Company has incurred and expects to continue to incur significant costs in pursuit of financing and acquisition
plans. Management plans to address this uncertainty during the period leading up to the Initial Business Combination. The Company cannot
provide any assurance that its plans to raise capital or to consummate an Initial Business Combination will be successful. Based on the
foregoing, management believes that the Company will not have sufficient working capital and borrowing capacity to meet its needs through
the earlier of the consummation of the Initial Business Combination or one year from this filing. These factors raise substantial doubt
about the Company’s ability to continue as a going concern.
NOTE 2 — ORGANIZATION AND SUMMARY OF
SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying audited financial statements have been prepared in
accordance with U.S. GAAP and in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”).
The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements.
Such condensed financial statements and accompanying notes are the representations of the Company’s management, who is responsible
for their integrity and objectivity.
Unaudited Interim Financial Statements
In the opinion of the Company,
the unaudited financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement
of its financial position as of June 30, 2023, and its results of operations for the three and six months ended June 30, 2023.
The
accompanying unaudited condensed financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K
for the year ended December 31, 2022 as filed with the SEC on March 31, 2023, which contains the audited financial statements and notes
thereto. The financial information as of December 31, 2022 is derived from the audited financial statements presented in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2022. The interim results for the three and six months ended June 30, 2023
are not necessarily indicative of the results to be expected for the year ending December 31, 2023 or for any future interim periods.
Emerging Growth Company
The Company is an “emerging
growth company,” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012
(the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable
to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the
auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive
compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote
on executive compensation and stockholder approval of any golden parachute payments not previously approved. Further, Section 102(b)(1)
of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until
private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class
of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS
Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period
which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company,
as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard.
This may make comparison of the Company’s financial statements with another public company which is neither an emerging growth company
nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential
differences in accounting standards used.
Use of Estimates
The preparation of financial
statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the
reported amounts of revenues and expenses during the reporting period. Making estimates requires management to exercise significant judgment.
It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the
date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or
more future confirming events. Accordingly, the actual results could differ significantly from those estimates.
Cash Equivalents
The Company considers all
short-term investments with an original maturity of three months or less when purchased to be cash equivalents. The Company did not have
any cash equivalents as of June 30, 2023 or December 31, 2022.
Marketable Securities Held in Trust Account
The Company has marketable securities held in the Trust Account consisting
of securities held in a money market fund that invests in U. S. governmental securities with a maturity of 180 days or less
which meet certain conditions under Rule 2a-7 under the Investment Company Act. Marketable securities held in the Trust Account are classified
as trading securities. Trading securities are presented on the balance sheets at fair value at the end of each reporting period. Gains
and losses resulting from the change in fair value of these securities and interest income are included in the condensed statements of
operations. The estimated fair values of the investments held in the Trust Account are determined using available market information.
Warrant Liabilities
The Company accounts for the
Private Warrants in accordance with the guidance contained in ASC 480 under which the Private Warrants do not meet the criteria for equity
treatment and must be recorded as derivative liabilities. Accordingly, upon issuance, the Company classified the Private Warrants as liabilities
at their fair value and will adjust the Private Warrants to fair value at each reporting period. This liability is subject to re-measurement
at each balance sheet date until the Private Warrants are exercised or expire, and any change in fair value is recognized in the Company’s
statements of operations. The fair value of the Private Warrants will be initially and subsequently measured at the end of each reporting
period using a Black-Scholes option pricing model.
The
Company accounts for the Public Warrants in accordance with the guidance contained in ASC 815-40 under which the Public Warrants meet
the criteria for equity treatment and are recorded as equity.
Common Stock Subject to Possible Redemption
The Company accounts for its
common stock subject to possible redemption in accordance with the guidance in ASC 480. Common stock subject to mandatory redemption is
classified as a liability instrument and is measured at fair value. Conditionally redeemable common stock (including common stock that
feature redemption rights that is either within the control of the holder or subject to redemption upon the occurrence of uncertain events
not solely within the Company’s control) is classified as temporary equity. At all other times, common stock is classified as stockholders’
equity. The Company’s common stock features certain redemption rights that are considered to be outside of the Company’s control
and subject to occurrence of uncertain future events. Accordingly, common stock subject to possible redemption will be presented at redemption
value and as temporary equity, outside of the stockholders’ equity (deficit) section of the Company’s balance sheets.
The Company has made a policy
election in accordance with ASC 480 and will accrete changes in redemption value in additional paid-in capital (or accumulated deficit
in the absence of additional paid-in capital) through the time period to complete the Initial Business Combination. In connection with
a redemption of shares, any unrecognized accretion will be fully recognized for shares that are redeemed. As of June 30, 2023, the Company
had recorded accretion of $609,172, with unrecognized accretion of $200,206 remaining.
Income Taxes
The Company follows the asset
and liability method of accounting for income taxes under ASC 740, Income Taxes. Deferred tax assets and liabilities are recognized
for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets
and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply
to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax
assets and liabilities of a change in tax rates is recognized in income in the period that included the enactment date. Valuation allowances
are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.
ASC 740 prescribes a recognition
threshold and a measurement attribute for the financial statement recognition and measurement of tax positions taken or expected to be
taken in a tax return. For those benefits to be recognized, a tax position must be more likely than not to be sustained upon examination
by taxing authorities. The Company recognizes accrued interest and penalties related to unrecognized tax benefits as income tax expense.
There were no unrecognized tax benefits and no amounts accrued for interest and penalties as of June 30, 2023 and December 31, 2022. The
Company is currently not aware of any issues under review that could result in significant payments, accruals or material deviation from
its position. The Company is subject to income tax examinations by taxing authorities since inception.
Concentration of Credit Risk
Financial instruments that
potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times,
may exceed the Federal Depository Insurance Coverage. As of June 30, 2023 and December 31, 2022, the Company had not experienced losses
on this account and management believes the Company is not exposed to significant risks on such account.
Fair Value of Financial Instruments
The fair value of the Company’s
assets and liabilities, which qualify as financial instruments under ASC 820, Fair Value Measurement, approximates the carrying
amounts represented in the accompanying balance sheet, primarily due to their short-term nature.
Fair Value Measurements
Fair value is defined as the
price that would be received for sale of an asset or paid for transfer of a liability, in an orderly transaction between market participants
at the measurement date. U.S. GAAP establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair
value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level
1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include:
|
● |
Level 1, defined as observable inputs such as quoted prices (unadjusted) for identical instruments in active markets; |
|
|
|
|
● |
Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and |
|
|
|
|
● |
Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. |
In some circumstances, the
inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair
value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the
fair value measurement.
Derivative Financial Instruments
The Company evaluates its
financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance
with ASC 815, Derivatives and Hedging. For derivative financial instruments that are accounted for as liabilities, the derivative
instrument is initially recorded at its fair value on the issuance date and is then re-valued at each reporting date, with changes in
the fair value reported in the statements of operations. The classification of derivative instruments, including whether such instruments
should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified
in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required
within 12 months of the balance sheet date.
Net Income (Loss) Per Share
Net loss per share is
computed by dividing net loss by the weighted average number of common shares outstanding during the reporting period. Diluted net
income (loss) per share is computed similar to basic income (loss) per share, except the weighted average number of common shares
outstanding are increased to include additional shares from the assumed exercise of share options, if dilutive. All outstanding
convertible notes are considered common stock at the beginning of the period or at the time of issuance, if later, pursuant to the
if-converted method. Since the effect of common stock equivalents is anti-dilutive with respect to losses, the shares issuable upon
conversion have been excluded from the Company’s computation of net loss per common share for the three and six months ended
June 30, 2023 and 2022.
The following table summarizes
the securities that would be excluded from the diluted per share calculation because the effect of including these potential shares was
antidilutive due to the Company’s net loss position, even though the exercise price could be less than the most recent fair value
of the common shares:
| |
As of June 30, 2023 | |
Potential shares from convertible debt | |
| 165,000 | |
Total | |
| 165,000 | |
| |
As of June 30, 2022 | |
Potential shares from convertible debt | |
| 80,000 | |
Total | |
| 80,000 | |
The statements of operations
include a presentation of loss per redeemable share and loss per non-redeemable share following the two-class method of loss per share.
In order to determine the net loss attributable to both the redeemable shares and non-redeemable shares, the Company first considered
the total loss allocable to both sets of shares. This is calculated using the total net loss less any dividends paid. For purposes of
calculating net loss per share, any remeasurement of the ordinary shares subject to possible redemption was considered to be dividends
paid to holders of redeemable common stock. For the three and six months ended June 30, 2023 and 2022, this had an antidilutive effect
on earnings per share for the non-redeemable shares. Therefore, the Company did not allocate any portion of the loss to the redeemable
shares subject to redemption.
For the three and six months
ended June 30, 2023 and 2022, the net loss per share included within the statements of operations is based on the following:
For the Three
Months Ended June 30, 2023
Net loss | | $ | (374,855 | ) |
Accretion of temporary equity to redemption value | | | (301,576 | ) |
Net loss including accretion of temporary equity to redemption value | | $ | (676,431 | ) |
| |
Common Shares Subject to
Redemption | | |
Non-redeemable
Common Shares | |
Basic and diluted net loss per share: | |
| | |
| |
Numerator: | |
| | |
| |
Allocation of net loss including accretion of temporary equity | |
$ | (284,233 | ) | |
$ | (392,198 | ) |
Accretion of temporary equity to redemption value | |
| 301,576 | | |
| — | |
Allocation of net income (loss) | |
$ | 17,343 | | |
$ | (392,198 | ) |
| |
| | | |
| | |
Denominator: | |
| | | |
| | |
Weighted-average shares outstanding | |
| 1,252,372 | | |
| 1,728,078 | |
Basic and diluted net income (loss) per share | |
$ | 0.01 | | |
$ | (0.23 | ) |
For the Three Months Ended June 30, 2022
Net loss | |
$ | (386,732 | ) |
Accretion of temporary equity to redemption value | |
| (1,195,374 | ) |
Net loss including accretion of temporary equity to redemption value | |
$ | (1,582,106 | ) |
| |
Common
Shares Subject to Redemption | | |
Non-
redeemable Common Shares | |
Basic and diluted net loss per share: | |
| | |
| |
Numerator: | |
| | |
| |
Allocation of net loss including accretion of temporary equity | |
$ | (1,215,716 | ) | |
$ | (366,390 | ) |
Accretion of temporary equity to redemption value | |
| 1,195,371 | | |
| — | |
Allocation of net loss | |
$ | (20,342 | ) | |
$ | (366,390 | ) |
| |
| | | |
| | |
Denominator: | |
| | | |
| | |
Weighted-average shares outstanding | |
| 5,733,920 | | |
| 1,728,078 | |
Basic and diluted net loss per share | |
$ | (0.00 | ) | |
$ | (0.21 | ) |
For the Six Months Ended June 30, 2023
Net loss | |
$ | (843,539 | ) |
Accretion of temporary equity to redemption value | |
| (609,172 | ) |
Net loss including accretion of temporary equity to redemption value | |
$ | (1,452,711 | ) |
| |
Common
Shares Subject to Redemption | | |
Non-
redeemable Common
Shares | |
Basic and diluted net loss per share: | |
| | |
| |
Numerator: | |
| | |
| |
Allocation of net loss including accretion of temporary equity | |
$ | (610,423 | ) | |
$ | (842,288 | ) |
Accretion of temporary equity to redemption value | |
| 609,172 | | |
| — | |
Allocation of net loss | |
$ | (1,251 | ) | |
$ | (842,288 | ) |
| |
| | | |
| | |
Denominator: | |
| | | |
| | |
Weighted-average shares outstanding | |
| 1,252,372 | | |
| 1,728,078 | |
Basic and diluted net loss per share | |
$ | (0.00 | ) | |
$ | (0.49 | ) |
For the Six Months Ended June 30, 2022
Net loss | |
$ | (1,709,339 | ) |
Accretion of temporary equity to redemption value | |
| (2,294,875 | ) |
Net loss including accretion of temporary equity to redemption value | |
$ | (4,004,214 | ) |
| |
Common
Shares Subject to Redemption | | |
Non- redeemable Common
Shares | |
Basic and diluted net income (loss) per share: | |
| | |
| |
Numerator: | |
| | |
| |
Allocation of net loss including accretion of temporary equity | |
$ | (3,076,903 | ) | |
$ | (927,311 | ) |
Accretion of temporary equity to redemption value | |
| 2,294,875 | | |
| — | |
Allocation of net loss | |
$ | (782,028 | ) | |
$ | (927,311 | ) |
| |
| | | |
| | |
Denominator: | |
| | | |
| | |
Weighted-average shares outstanding | |
| 5,733,920 | | |
| 1,728,078 | |
Basic and diluted net loss per share | |
$ | (0.14 | ) | |
$ | (0.54 | ) |
As of June 30, 2023 and 2022,
any securities and other contracts that could, potentially, be exercised or converted into common stock would be antidilutive due to the
Company’s loss position. As a result, diluted loss per share is the same as basic loss per share for the periods presented.
Recent Accounting Pronouncements
Management does not believe
that any recently issued, but not yet effective, accounting pronouncements, if currently adopted, would have a material effect on the
Company’s unaudited financial statements.
NOTE 3 — RELATED PARTY TRANSACTIONS
Promissory Notes — Related Party
On August 5 and November 1
of 2022, the Company entered into a promissory note with its Sponsor of principal amounts received of $573,392 for each note to extend
the time available for the Company to consummate its Initial Business Combination. The notes are non-interest bearing, unsecured and payable
on the date the Company consummates an Initial Business Combination.
On February 10, March 10, April 10, May 12, and June 9 of 2023, the
Company entered into five promissory notes with its Sponsor of principal amounts received of $87,500 for each note to extend the
time available for the company to consummate its initial business combination. The notes are non-interest bearing, unsecured and payable
on the date the Company consummates an Initial Business Combination.
In the event that an Initial
Business Combination does not close prior to February 12, 2024 (or later if the period of time to consummate an Initial Business Combination
is extended), the notes shall be deemed terminated and no amounts will be owed. As of June 30 2023, there was $1,584,284 outstanding
in the aggregate under the notes.
Convertible Promissory Notes — Related
Party
During 2022, the Company entered
into four convertible promissory notes with its Sponsor for aggregate principal amounts received of $1,250,000 (the “2022 Convertible
Promissory Notes”). The first convertible promissory note of $300,000 was used for a portion of the expenses of the IPO. The
remaining borrowings were used for operating expenses. All of the notes are non-interest bearing, unsecured and payable on the date the
Company consummates a Business Combination. In the event that a Business Combination does not close prior to February 12, 2024, the notes
shall be deemed terminated and no amounts will be owed. At any time, up to a day prior to the closing of an Initial Business Combination,
the holder may convert the principal amounts into private units of the Company at a conversion price of $10.00 per unit. As of June
30, 2023 and December 31, 2022, there was $1,250,000 outstanding under the 2022 Convertible Promissory Notes.
During 2023, the Company entered
into three convertible promissory notes with its Sponsor of aggregate principal amounts of $400,000 to be used for operating expenses
(the “2023” Convertible Promissory Notes”). The 2023 Convertible Promissory Notes carry the same terms as the 2022 Convertible
Promissory Notes. As of June 30, 2023 and December 31, 2022, there was $400,000 and $0, respectively, outstanding under the 2023
Convertible Promissory Notes.
Administrative and Support Services
The Company entered into an
administrative services agreement pursuant to which the Company will pay the Sponsor a total of $10,000 per month for office space,
administrative and support services, which the Company records as operating expense on its statements of operations. Upon the completion
of the Initial Business Combination or our liquidation, the Company will cease paying these monthly fees. The Company recorded $30,000
and $60,000 related to these fees during the three and six months ended June 30, 2023 and 2022. As of June 30, 2023 and December
31, 2022, the Company owed the Sponsor $70,000 and $10,000, respectively, under this agreement, which is included in accounts payable
and accrued expenses in the accompanying balance sheets.
NOTE 4 — COMMITMENTS AND CONTINGENCIES
Merger Agreement with DLQ
On September 9, 2022, the
Company, entered into a Merger Agreement (the “Merger Agreement”) by and among Abri Merger Sub, Inc., a Delaware corporation
and a wholly owned subsidiary of Abri (“Merger Sub”), Logiq, Inc., a Delaware corporation (“DLQ Parent”) whose
common stock is quoted on the OTCQX Market under the ticker symbol, “LGIQ”, and DLQ, Inc., a Nevada corporation (“DLQ”)
and wholly owned subsidiary of DLQ Parent. Pursuant to the terms of the Merger Agreement, a business combination between the Company and
DLQ will be effected through the merger of Merger Sub with and into DLQ, with DLQ surviving the merger as a wholly owned subsidiary of
the Company (the “Merger”). The board of directors of the Company has (i) approved and declared advisable the Merger Agreement,
the Additional Agreements (as defined in the Merger Agreement) and the transactions contemplated thereby and (ii) resolved to recommend
approval of the Merger Agreement and related transactions by the stockholders of the Company.
The Merger is expected to
be consummated after obtaining the required approval by the stockholders of the Company, DLQ and DLQ Parent and the satisfaction of certain
other customary closing conditions.
The total consideration to
be paid at Closing (the “Merger Consideration”) by the Company to DLQ security holders will be an amount equal to $114,000,000.
The Merger Consideration will be payable in shares of common stock, par value $0.0001 per share, of the Company (“Abri Common
Stock”).
DLQ Management Earnout Agreement
In connection with the execution
of the Merger Agreement, Abri and the Sponsor will enter into a management earnout agreement (the “Management Earnout Agreement”),
pursuant to which certain members of the management team of DLQ specified on schedule A to the Management Earnout Agreement (the “Management”)
will have the contingent right to earn the Management Earnout Shares (as defined in the Management Earnout Agreement). The Management
Earnout Shares consist of 2,000,000 shares of Abri Common Stock (the “Management Earnout Shares”). The release of
the Management Earnout Shares shall occur as follows:
| ● | 500,000 Management
Earnout Shares will be earned and released upon satisfaction of the First Milestone Event (as defined in the Management Earnout Agreement); |
| ● | 650,000 Management
Earnout Shares will be earned and released upon satisfaction of the Second Milestone Event (as defined in the Management Earnout Agreement);
and |
| ● | 850,000 Management
Earnout Shares will be earned and released upon satisfaction of the Third Milestone Event (as defined in the Management Earnout Agreement). |
If the Company has not consummated
an initial business combination by February 12, 2024, the Company will be required to dissolve and liquidate.
Registration Rights
The holders of the Founder
Shares are entitled to registration rights pursuant to a registration rights agreement that was signed as of the effective date of the
IPO. The holders of the majority of these securities are entitled to make up to three demands that the Company register such securities.
The holders of the majority of the Founder Shares can elect to exercise these registration rights at any time commencing three months
prior to the date on which the Founder Shares are to be released from escrow. In addition, the holders have certain “piggy-back”
registration rights with respect to registration statements filed subsequent to our consummation of our Initial Business Combination.
The holders of the Founder Shares have agreed not to transfer, assign or sell any of the such shares (except to certain permitted transferees)
until, with respect to 50% of such shares, the earlier of six months after the date of the consummation of our Initial Business Combination
and the date on which the closing price of our common stock equals or exceeds $12.50 per share for any 20 trading days within a 30-trading
day period following the consummation of our Initial Business Combination and, with respect to the remaining 50% of such shares,
six months after the date of the consummation of our Initial Business Combination, or earlier in each case if, subsequent to our Initial
Business Combination, we complete a liquidation, merger, stock exchange or other similar transaction which results in all of our stockholders
having the right to exchange their shares of common stock for cash, securities or other property. The Founder Shares will be held in escrow
with Continental Stock Transfer & Trust Company during the period in which they are subject to the transfer restrictions described
above.
Unit Purchase Option
We sold to the underwriters,
for $100, an option to purchase up to a total of 300,000 units (increased to 344,035 units after the over-allotment
was exercised in part) exercisable, in whole or in part, at $11.50 per unit, commencing on the consummation of our Initial Business
Combination. The purchase option may be exercised for cash or on a cashless basis, at the holder’s option, and expires five
years from the commencement of sales in this offering. The option and the 300,000 units, as well as the 300,000 shares
of common stock, and the warrants to purchase 300,000 shares of common stock that may be issued upon exercise of the option,
have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately following the effective
date of the registration statement or the commencement of sales in the IPO pursuant to Rule 5110(e)(1) of FINRA’s Rules, during
which time the option may not be sold, transferred, assigned, pledged or hypothecated, or be subject of any hedging, short sale, derivative
or put or call transaction that would result in the economic disposition of the securities. Additionally, the option may not be sold,
transferred, assigned, pledged or hypothecated for a one-year period (including the foregoing 180-day period) following the date of the
Company’s initial prospectus except to any underwriter and selected dealer participating in the offering and their bona fide officers
or partners. The option grants to holders demand and “piggy-back” rights of the securities directly and indirectly issuable
upon exercise of the option. Notwithstanding the foregoing, the underwriters and their related persons may not (i) have more than
one demand registration right at our expense, (ii) exercise their demand registration rights more than five (5) years from the effective
date of the registration statement, and (iii) exercise their “piggy-back” registration rights more than seven (7) years from
the effective date of the registration statement. We will bear all fees and expenses attendant to registering the securities, other
than underwriting commissions which will be paid for by the holders themselves. The exercise price and number of units issuable upon exercise
of the option may be adjusted in certain circumstances including in the event of a stock dividend, or our recapitalization, reorganization,
merger or consolidation. However, the option will not be adjusted for issuances of shares of common stock at a price below its exercise
price. We will have no obligation to net cash settle the exercise of the purchase option or the warrants underlying the purchase option.
The holder of the purchase option will not be entitled to exercise the purchase option or the warrants underlying the purchase option
unless a registration statement covering the securities underlying the purchase option is effective or an exemption from registration
is available. If the holder is unable to exercise the purchase option or underlying warrants, the purchase option or warrants, as applicable,
will expire worthless.
On August 12, 2021, the Company
accounted for the unit purchase option, inclusive of the receipt of $100 cash payment, as an expense of the Initial Public Offering
resulting in a charge directly to stockholders’ equity.
NOTE 5 — STOCKHOLDERS’ DEFICIT
Common Stock
The Company has authorized 100,000,000 shares
of common stock, par value $0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.0001 per share.
Public and Private Warrants
Each whole warrant entitles
the registered holder to purchase one common stock at a price of $11.50 per share, subject to adjustment as discussed below, at any
time commencing on the later of the completion of an Initial Business Combination and one year from the consummation of the
Company’s IPO. The warrants will expire five years after the completion of our Initial Business Combination, or earlier
upon redemption.
No public warrants will be
exercisable for cash unless we have an effective and current registration statement covering the shares of common stock issuable upon
exercise of the warrants and a current prospectus relating to such shares. It is our current intention to have an effective and current
registration statement covering the shares of common stock issuable upon exercise of the warrants and a current prospectus relating to
such shares in effect promptly following consummation of an Initial Business Combination. Notwithstanding the foregoing, if a registration
statement covering the shares of common stock issuable upon exercise of the public warrants is not effective within 90 days following
the consummation of our Initial Business Combination, public warrant holders may, until such time as there is an effective registration
statement and during any period when we shall have failed to maintain an effective registration statement, exercise warrants on a cashless
basis.
We may redeem the outstanding
warrants, in whole and not in part, at a price of $0.01 per warrant:
| ● | at
any time while the warrants are exercisable; |
| ● | upon
a minimum of 30 days’ prior written notice of redemption; |
| ● | if, and only if, the last sales price of our shares of common
stock equals or exceeds $16.50 per share for any 20 trading days within a 30-trading day period ending three business days before we
send the notice of redemption; and |
| ● | if, and only if, there is a current registration statement
in effect with respect to the shares of common stock underlying such warrants at the time of redemption and for the entire 30-day trading
period referred to above and continuing each day thereafter until the date of redemption. |
If the foregoing conditions
are satisfied and we issue a notice of redemption, each warrant holder can exercise his, her or its warrant prior to the scheduled redemption
date. However, the price of the shares of common stock may fall below the $16.50 trigger price as well as the $11.50 warrant
exercise price per share after the redemption notice is issued and not limit our ability to complete the redemption.
The redemption criteria for
our warrants have been established at a price which is intended to provide warrant holders a reasonable premium to the initial exercise
price and provide a sufficient differential between the then-prevailing share price and the warrant exercise price so that if the share
price declines as a result of our redemption call, the redemption will not cause the share price to drop below the exercise price of the
warrants.
If we call the warrants for
redemption as described above, our management will have the option to require all holders that wish to exercise warrants to do so on a
“cashless basis.” In such event, each holder would pay the exercise price by surrendering the whole warrants for that number
of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying
the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined
below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the shares
of common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to
the holders of warrants. Whether we will exercise our option to require all holders to exercise their warrants on a “cashless basis”
will depend on a variety of factors including the price of our shares of common stock at the time the warrants are called for redemption,
our cash needs at such time and concerns regarding dilutive share issuances.
Common Stock Subject to Redemption
The Company’s common
stock feature certain redemption rights that are considered to be outside of the Company’s control and subject to the occurrence
of future events. The Company is authorized to issue 100,000,000 shares of common stock with a par value of $0.0001 per
share. Holders of the Company’s common stock are entitled to one vote for each share. As of June 30, 2023 and December
31, 2022, there were 1,252,372 shares of common stock outstanding subject to possible redemption and are classified outside
of permanent equity in the balance sheets.
The balances of common stock
subject to possible redemption reflected on the balance sheets are reconciled in the following table:
Common stock subject to possible redemption as of December 31, 2021 | |
$ | 52,323,289 | |
Plus: | |
| | |
Accretion of common stock subject to possible redemption | |
| 6,470,389 | |
Less: | |
| | |
Common stock redeemed on December 19, 2022 | |
| (45,952,279 | ) |
Common stock subject to possible redemption as of December 31, 2022 | |
| 12,841,399 | |
Plus: | |
| | |
Accretion of common stock subject to possible redemption | |
| 609,172 | |
Common stock subject to possible redemption as of June 30, 2023 | |
$ | 13,450,571 | |
NOTE 6 — WARRANTS
On August 12, 2021, the Company
consummated its IPO of 5,000,000 Units at $10.00 per Unit, generating gross proceeds of $50,000,000, with each Unit consisting
of one share of common stock, $0.0001 par value, and one redeemable warrant. The Company granted the underwriter a 45-day option
to purchase up to an additional 750,000 Units at the IPO price to cover over-allotments.
Simultaneously with the consummation
of the closing of the IPO, the Company completed the private sale of 276,250 Private Units to its Sponsor at a purchase price
of $10.00 per Private Unit, generating gross proceeds to the Company of $2,762,500, with each Private Unit consisting of one share
of common stock, $0.0001 par value, and one redeemable warrant.
Upon consummation of our IPO,
we sold to the underwriters, for $100, an option to purchase up to a total of 300,000 units (increased to 344,035 units
after the over-allotment was exercised in part) exercisable, in whole or in part, at $11.50 per unit, commencing on the consummation
of our Initial Business Combination. The purchase option may be exercised for cash or on a cashless basis, at the holder’s option,
and expires five years from the commencement of sales in this offering. The option and the 300,000 units, as well
as the 300,000 shares of common stock, and the warrants to purchase 300,000 shares of common stock that may be issued
upon exercise of the option have been deemed compensation by FINRA and are therefore subject to a lock-up for a period of 180 days immediately
following the effective date of our registration statement, or August 9, 2021. As of August 12, 2021, the Company accounted for the unit
purchase option, inclusive of the receipt of $100 cash payment, as an expense of the IPO resulting in a charge directly to stockholders’
equity.
On August 19, 2021, the underwriters
notified the Company of their intent to exercise of the over-allotment option in part and, on August 23, 2021, the underwriters purchased 733,920 Additional
Units at $10.00 per Additional Unit upon the closing of the over-allotment option, generating additional gross proceeds of $7,339,200.
On August 23, 2021, simultaneously with the sale of the Additional Units, the Company consummated the sale of an additional 18,348 Additional
Private Units, generating additional gross proceeds of $183,480, with each Additional Private Unit consisting of one share of common stock,
$0.0001 par value, and one redeemable warrant.
On April 13, 2022, the Company
and Continental Stock Transfer & Trust Company (the “Warrant Agent”), entered into a supplement (the “Supplement
to Warrant Agreement”) to the Warrant Agreement, dated as of August 9, 2021 by and between the Company and the Warrant Agent in
connection with the Company’s IPO. The Supplement to Warrant Agreement is being made pursuant to Section 9.8 of the Warrant Agreement
which states the Warrant Agreement may be amended by the parties thereto by executing a supplemental warrant agreement without the consent
of any of the warrant holders. The Supplement to Warrant Agreement is being executed solely to correct an ambiguity provision contained
in Section 2.5 of the Warrant Agreement to clarify that the lock-up period for the Private Warrants extends to 30 days after the completion
of the Company’s Initial Business Combination.
Each Private Unit, Additional
Unit and Additional Private Unit are identical to the Unit from our IPO except as described below.
The Sponsor has agreed to
waive its redemption rights with respect to any shares underlying the Private Units (i) in connection with the consummation of a business
combination, (ii) in connection with a stockholder vote to amend our amended and restated certificate of incorporation to modify the substance
or timing of our obligation to allow redemption in connection with our Initial Business Combination or certain amendments to our charter
prior thereto, to redeem 100% of our public shares if we do not complete our Initial Business Combination within 12 months from the completion
of this offering (or up to 18 months from the closing of this offering if extended) or with respect to any other provision relating to
stockholders’ rights or pre-Initial Business Combination activity and (iii) if we fail to consummate a business combination within
12 months from the completion of this offering (or up to 18 months from the closing of this offering if extended) or if we liquidate prior
to the expiration of the 18 month period. However, the Sponsor will be entitled to redemption rights with respect to any public shares
it holds if we fail to consummate a business combination or liquidate within the 18-month period.
The Private Units and their
component securities will not be transferable, assignable or saleable until 30 days after the consummation of our Initial Business Combination
except to permitted transferees.
The Company evaluated the
Public and Private Warrants as either equity-classified or liability-classified instruments based on an assessment of the warrants’
specific terms and ASC 480 and ASC 815. The assessment considers whether the warrants are freestanding financial instruments pursuant
to ASC 480, meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification
under ASC 815, including whether the warrants are indexed to the Company’s own common stock, among other conditions for equity classification.
Pursuant to such evaluation, the Company further evaluated the Public and Private Warrants under ASC 815-40, Derivatives and Hedging
— Contracts in Entity’s Own Equity and concluded that the Private Warrants do not meet the criteria to be classified
in stockholders’ equity (deficit).
Certain adjustments to the
settlement amount of the Private warrants are based on a variable that is not an input to the fair value of an option as defined under
ASC 815 — 40, and thus the warrants are not considered indexed to the Company’s own stock and not eligible for an exception
from derivative accounting. The accounting treatment of derivative financial instruments requires that the Company record a derivative
liability upon issuance of the warrants at the closing of the IPO. Accordingly, the Company classified each Private Warrant as a liability
at its fair value, with subsequent changes in their respective fair values recognized in the statements of operations and comprehensive
income (loss) at each reporting date.
The Company accounted for
the Public Warrants as equity based on its initial evaluation that the Public Warrants are indexed to the Company’s own stock. The
fair value of the Public Warrants was approximately $0.60 per Public Warrant, which was determined by the Monte Carlo simulation
model. The Public Warrants will be recorded at the amount of allocated proceeds and will not be remeasured every reporting period.
NOTE 7 — FAIR VALUE MEASUREMENTS
The Company carries cash equivalents,
marketable investments, Private Warrants, at fair value. Fair value is based on the price that would be received from selling an asset
or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is estimated
by applying the following hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization
within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.
The Company determined the fair value of its Level 1 financial instruments,
which are traded in active markets, using quoted market prices for identical instruments. The Company’s Marketable Securities held
in Trust Account is classified within Level 1 of the fair value hierarchy.
The Company’s Private Warrants are valued
as Level 2 instruments.
The estimated fair value of the
Private Warrants is determined using Level 2 inputs for the period ended June 30, 2023. Inherent in a Black-Scholes pricing model are
assumptions related to dividend yield, term, volatility and risk-free rate, which results in the call option value. The Company estimates
the volatility of its common shares based on management’s understanding of the volatility associated with instruments of other similar
entities. The risk-free interest rate is based on the U.S. Treasury rate matching the expected term of the warrants. The expected life
of the warrants is simulated based on management assumptions regarding the timing and likelihood of completing our Initial Business Combination.
The dividend rate is based on the historical rate, which the Company anticipates remaining at zero.
The fair value and call option
value of the Private Warrants as of June 30, 2023 was $10,311, which was determined by the Black-Scholes Pricing Model with the following
assumptions: dividend yield of 0%, term of 1.25 years, volatility of 1.4%, exercise price of $11.50 and risk-free
rate of 5.27%, resulting in a gain on the change in fair value of warrant liability of $16,203 and $7,365 for the three and six months
ended June 30, 2023, respectively. The fair value and call option value of the Private Warrants
as of June 30, 2022 was $61,865, which was determined by the Black-Scholes Pricing Model with the following assumptions: dividend yield
of 0%, term of 4.75 years, volatility of 2.5%, exercise price of $11.50 and risk-free rate of 3.01%, resulting
in a gain on change in fair value of warrant liability of $41,244 and $109,002 for the three and six months ended June 30, 2022,
respectively.
The following table presents
the change in fair value from December 31, 2022 to June 30, 2023:
| |
Warrant
liabilities | |
Level 2 financial instruments as of December 31, 2022 | |
$ | 17,676 | |
Change in fair value | |
| 8,838 | |
Level 2 financial instruments as of March 31, 2023 | |
| 26,514 | |
Change in fair value | |
| (16,203 | ) |
Level 2 financial instruments as of June 30, 2023 | |
$ | 10,311 | |
Transfers to/from Levels 1, 2,
and 3 are recognized at the beginning of the reporting period. There were no transfers during the three and six months ended June 30,
2023. The Company transferred the Private Warrants from Level 3 to Level 2 during the three months ended June 30, 2022, as the inputs
significant to the valuation became observable as they are benchmarked to those used for the Public Warrants.
The following table presents
the transfers and the change in fair value from December 31, 2021 to June 30, 2022:
|
|
Warrant liabilities |
|
|
|
|
|
Level 3 financial instruments as of December 31, 2021 |
|
$ |
170,867 |
|
Change in fair value |
|
|
(67,758 |
) |
Level 3 financial instruments as of March 31, 2022 |
|
|
103,109 |
|
Change in fair value |
|
|
(41,244 |
) |
Transfer to Level 2 |
|
|
(67,865 |
) |
Level 3 financial instruments as of June 30, 2022 |
|
$ |
- |
|
The following table presents
information about the Company’s assets that are measured at fair value on a recurring basis at June 30, 2023 and indicates the fair
value hierarchy of the valuation inputs the Company utilized to determine such fair value:
| |
| | |
Fair value measurements at reporting date using: | |
Description | |
Fair Value | | |
Quoted prices in active markets for identical liabilities (Level 1) | | |
Significant other observable inputs (Level 2) | | |
Significant unobservable inputs (Level 3) | |
Assets: | |
| | |
| | |
| | |
| |
Marketable securities held in Trust Account | |
$ | 13,650,778 | | |
$ | 13,650,778 | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Warrant liabilities | |
$ | 10,311 | | |
$ | - | | |
$ | 10,311 | | |
$ | - | |
The following table presents
information about the Company’s assets that are measured at fair value on a recurring basis at December 31, 2022 and indicates the
fair value hierarchy of the valuation inputs the Company utilized to determine such fair value:
| |
| | |
Fair value measurements at
reporting date using: | |
Description | |
Fair Value | | |
Quoted prices in active markets for identical liabilities (Level 1) | | |
Significant other observable inputs (Level 2) | | |
Significant unobservable inputs (Level 3) | |
Assets: | |
| | |
| | |
| | |
| |
Marketable securities held in Trust Account | |
$ | 12,841,399 | | |
$ | 12,841,399 | | |
$ | - | | |
$ | - | |
| |
| | | |
| | | |
| | | |
| | |
Liabilities: | |
| | | |
| | | |
| | | |
| | |
Warrant liabilities | |
$ | 17,676 | | |
$ | - | | |
$ | 17,676 | | |
$ | - | |
NOTE 8 — INCOME TAXES
The Company’s effective
tax rate for the three months ended June 30, 2023 and 2022 was 7% and 0%, respectively. The Company’s effective tax rate for the
six months ended June 30, 2023 and 2022, was 6% and 0%, respectively. The Company’s effective tax rate differs from the statutory
income tax rate of 21% primarily due to the recording of a full valuation allowance on deferred tax assets.
The Company has evaluated
its income tax positions and has determined that it does not have any uncertain tax positions. The Company will recognize interest and
penalties related to any uncertain tax positions through its income tax expense.
The Company files income tax
returns in the U.S. and Delaware jurisdictions and is subject to examination by the various taxing authorities since inception.
On August 16, 2022, President
Biden signed into law the Inflation Reduction Act of 2022, which includes a 15% minimum tax on the adjusted financial statement income
of corporations with a three taxable year average annual adjusted financial statement income in excess of $1 billion, a 1% excise tax
on net stock repurchases made by publicly traded US corporations and several tax incentives to promote clean energy. The alternative minimum
tax and the excise tax are effective in taxable years beginning after December 31, 2022. While these tax law changes have no immediate
effect and are not expected to have a material adverse effect on our results of operations going forward, we will continue to evaluate
its impact as further information becomes available.
NOTE 9 — SUBSEQUENT EVENTS
Management evaluated subsequent
events and transactions that occurred after the balance sheet date, up to the date that the financial statements were issued. Based upon
this review, other than as set forth below, management did not identify any subsequent events that would have required adjustment or
disclosure in the financial statements.
On July 11, 2023, the Company
entered into a convertible promissory note with its Sponsor for aggregate principal amount of $100,000. The notes is non-interest bearing,
unsecured and payable on the date the Company consummates a Business Combination. In the event that a Business Combination does not close
prior to February 12, 2024, the notes shall be deemed terminated and no amounts will be owed. At any time, up to a day prior to the closing
of an Initial Business Combination, the holder may convert the principal amounts into private units of the Company at a conversion price
of $10.00 per unit.
On July 31, 2023, the Company
entered into a convertible promissory note with its Sponsor for aggregate principal amount of $11,250. The notes is non-interest bearing,
unsecured and payable on the date the Company consummates a Business Combination. In the event that a Business Combination does not close
prior to February 12, 2024, the notes shall be deemed terminated and no amounts will be owed. At any time, up to a day prior to the closing
of an Initial Business Combination, the holder may convert the principal amounts into private units of the Company at a conversion price
of $10.00 per unit.
On July 10, 2023, the Company entered into a sixth promissory note
with its Sponsor of a principal amount received of $87,500 to extend the time available for the Company to consummate its Initial
Business Combination. The note is non-interest bearing, unsecured and payable on the date the Company consummates an Initial Business
Combination.
On August 7, 2023, the Company held a special meeting of stockholders
to extend the time to complete a business combination from August 12, 2023 to February 12, 2024 with no additional payment to the Company’s
trust account. In connection with the stockholders’ vote, 570,224 shares were tendered for redemption. As a result, $6,055,325 ($10.62
per share), after deducting allowable taxes, will be removed from the Company’s Trust Account to pay such holders. Following the
redemptions, the Company will have 682,148 public shares of common stock outstanding and $7,243,869 shall remain in the Trust Account.
ITEM 2. Management’s Discussion and Analysis
of Financial Condition and Results of Operations
References in this report
(this “Quarterly Report”) to “we,” “us” or the “Company” refer to Abri SPAC I, Inc. References
to our “management” or our “management team” refer to our officers and directors, and references to the “Sponsor”
refer to Abri Ventures I, LLC. The following discussion and analysis of the Company’s financial condition and results of operations
should be read in conjunction with the unaudited condensed financial statements and the notes thereto contained elsewhere in this Quarterly
Report. Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve
risks and uncertainties.
Special Note Regarding Forward-Looking Statements
This Quarterly Report includes
“forward-looking statements” that are not historical facts and involve risks and uncertainties that could cause actual results
to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Quarterly
Report including, without limitation, statements in this “Management’s Discussion and Analysis of Financial Condition and
Results of Operations” regarding the Company’s financial position, business strategy and the plans and objectives of management
for future operations, are forward-looking statements. Words such as “expect,” “believe,” “anticipate,”
“intend,” “estimate,” “seek” and variations and similar words and expressions are intended to identify
such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management’s
current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ
materially from the events, performance and results discussed in the forward-looking statements. For information identifying important
factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to
the Risk Factors section of the Company’s final prospectus for its Initial Public Offering (as defined below) filed with the U.S.
Securities and Exchange Commission (the “SEC”). The Company’s filings with the SEC can be accessed on the EDGAR section
of the SEC’s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention
or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
Overview
We are a blank check company
incorporated on March 18, 2021 as a Delaware corporation and formed for the purpose of entering into a merger, share exchange, asset acquisition,
stock purchase, recapitalization, reorganization or similar Business Combination with one or more businesses or IPO and the sale of the
Private Placement Units, our capital stock, debt or a combination of cash, stock and debt.
As
of June 30, 2023, and the date of this filing, we had not commenced operations. All activity for the period from March 18, 2021 (inception)
through June 30, 2023 related to organizational activities, activities necessary to consummate the initial public offering (“IPO”),
and to identify a target company for a business combination. We will not generate any operating revenues until after the completion of
our Initial Business Combination, at the earliest. We generate non-operating income in the form of interest income on marketable securities
held in the Trust Account.
We
continue to evaluate the impact of the Russia-Ukraine war on the industry and have concluded that, while it is reasonably possible that
such could have negative effects on our financial position, results of operations, and/or search for a target company, the specific impacts
are not readily determinable as of the date of these financial statements. The financial statements do not include any adjustments that
might result from the outcome of these uncertainties.
On August 12, 2021, simultaneously
with the consummation of the IPO, we sold to our Sponsor in a Private Placement 276,250 Private Units at a purchase price of $10.00 per
Private Unit, generating gross proceeds to the Company of $2,762,500. The Private Units are identical to the Public Units.
On
August 19, 2021, the underwriters notified us of their intent to exercise of the over-allotment option in part and, on August 23, 2021,
the underwriters purchased 733,920 additional Units (the “Additional Units”) at $10.00 per Additional Unit upon the closing
of the over-allotment option, generating additional gross proceeds of $7,339,200. On August 23, 2021, simultaneously with the sale of
the Additional Units, we consummated the sale of an additional 18,348 Private Units at $10.00 per additional Private Unit (the “Additional
Private Units”), generating additional gross proceeds of $183,480. A total of $7,339,200 of the net proceeds from the sale of the
Additional Units and the Additional Private Units was deposited in the Trust Account, bringing the aggregate proceeds held in the Trust
Account on that date to $57,339,200.
On
September 9, 2022, we entered into a Merger Agreement (the “Merger Agreement”) by and among Abri Merger Sub, Inc., a Delaware
corporation and a wholly owned subsidiary of Abri (“Merger Sub”), Logiq, Inc., a Delaware corporation (“DLQ Parent”)
whose common stock is quoted on the OTCQX Market under the ticker symbol, “LGIQ”, and DLQ, Inc., a Nevada corporation (“DLQ”)
and wholly owned subsidiary of DLQ Parent. Pursuant to the terms of the Merger Agreement, a business combination between us and DLQ will
be effected through the merger of Merger Sub with and into DLQ, with DLQ surviving the merger as a wholly owned subsidiary Abri (the “Merger”).
The board of directors of the Company have (i) approved and declared advisable the Merger Agreement, the Additional Agreements (as defined
in the Merger Agreement) and the transactions contemplated thereby and (ii) resolved to recommend approval of the Merger Agreement and
related transactions by the stockholders of the Company.
The
total consideration to be paid at Closing (the “Merger Consideration”) by us to DLQ security holders will be an amount equal
to $114,000,000. The Merger Consideration will be payable in 11,400,000 shares of common stock, par value $0.0001 per share,
of Abri (“Abri Common Stock”).
On
December 9, 2022, we held a special meeting of stockholders at which such stockholders voted to amend our amended and restated certificate
of incorporation and investment trust agreement, giving us the right to extend the date by which we must complete our Initial Business
Combination up to six times for an additional one month each time, from February 12, 2023 to August 12, 2023, by depositing $87,500 into
the Trust Account for each one-month extension. In connection with the special meeting, 4,481,548 shares of common stock were tendered
for redemption, resulting in redemption payments of $45,952,279 out of the Trust Account. On August 7, 2023, we held a second special
meeting of stockholders at which such stockholders voted to amend our amended and restated certificate of incorporation and investment
trust agreement, giving us the right to extend the date by which we must complete our Initial Business Combination from August 12, 2023
to February 12, 2024 with no additional payment to the Trust Account. As of the date of these financial statements were filed, we have
made the necessary deposits to extend our Initial Business Combination date to February 12, 2024.
If
we have not consummated an initial business combination by February 12, 2024, we will be required to dissolve and liquidate.
Results of Operations
Our only activities from March
18, 2021 (inception) through June 30, 2023 were organizational activities, those necessary to consummate the IPO and identify a target
company for a Business Combination. We do not expect to generate any operating revenues until after the completion of our Initial Business
Combination. We generate non-operating income in the form of interest income on marketable securities held in the Trust Account. We are
incurring expenses as a result of being a public company (for legal, financial reporting, accounting and auditing compliance), as well
as for due diligence expenses.
For the three months ended
June 30, 2023, we had a net loss of $374,855, which consisted of operating costs of $528,049 and income tax expense of $24,000, offset
by a change in fair value of warrant liabilities of $16,203 and interest income on marketable securities held in the Trust Account of
$160,991.
For the three months ended
June 30, 2022, we had a net loss of $386,732, which consisted of operating costs of $504,605, offset by interest income on cash held in
the Trust Account of $76,629 and a change in fair value of warrant liability of $41,244.
For the six months ended June
30, 2023, we had a net loss of $843,539, which consisted of operating costs of $1,105,905 and income tax expense of $48,000, offset by
a change in fair value of warrant liabilities of $7,365 and interest income on marketable securities held in the Trust Account of $303,001.
For the six months ended June
30, 2022, we had a net loss of $1,709,339, which consisted of operating costs of $1,900,314, offset by interest income on cash held in
the Trust Account of $81,973 and a change in fair value of warrant liability of $109,002.
Liquidity and Capital Resources
As of June 30, 2023, we had cash
of $148,389 and a working capital deficiency of $2,743,844. As of June 30, 2023, we had marketable securities held in the Trust Account
of $13,650,778 consisting of securities held in a money market fund and government bonds that invests in United States government treasury
bills, bonds or notes with a maturity of 180 days or less. Interest income on the balance in the Trust Account may be used by us to pay
taxes. Through June 30, 2023, we have withdrawn a cumulative amount of $400,000 of interest earned on the Trust Account to pay our taxes,
of which $139,478 has been withdrawn for future tax obligations and is classified as cash as of June 30, 2023 in the accompanying condensed
balance sheet. We intend to use substantially all of the funds held in the Trust Account to acquire a target business and to pay our expenses
relating thereto. To the extent that our capital stock is used in whole or in part as consideration to effect a Business Combination,
the remaining funds held in the Trust Account will be used as working capital to finance the operations of the target business. Such working
capital funds could be used in a variety of ways including continuing or expanding the target business’ operations, for strategic
acquisitions and for marketing, research and development of existing or new products. Such funds could also be used to repay any operating
expenses or finders’ fees which we had incurred prior to the completion of our Business Combination if the funds available to us
outside of the Trust Account were insufficient to cover such expenses.
Cash used in operating activities
for the six months ended June 30, 2023 was $261,025. Our operational liquidity needs were primarily satisfied through $400,000 of proceeds
from convertible promissory notes from a related party. During the six months ended June 30, 2023, proceeds of $437,500 from non-convertible
promissory notes were deposited into the Trust Account, in addition to $303,001 of interest income. We expect that we will need additional
capital to satisfy our liquidity needs if we do not consummate our Initial Business Combination prior to February 12, 2024. Although certain
of our initial stockholders, officers and directors or their affiliates have committed to loan us funds from time to time or at any time,
in whatever amount they deem reasonable in their sole discretion, there is no guarantee that we will receive such funds.
Off-Balance Sheet Financing Arrangements
We have no obligations, assets
or liabilities, which would be considered off-balance sheet arrangements as of June 30, 2023 and December 31, 2022. We do not participate
in transactions that create relationships with unconsolidated entities or financial partnerships, often referred to as variable interest
entities, which would have been established for the purpose of facilitating off-balance sheet arrangements. We have not entered into any
off-balance sheet financing arrangements, established any special purpose entities, guaranteed any debt or commitments of other entities,
or purchased any non-financial assets.
Contractual Obligations
We do not have any long-term
debt, capital lease obligations, operating lease obligations or long-term liabilities other than an agreement to pay our Sponsor a monthly
fee of $10,000 for office space, utilities and secretarial and administrative support. We incurred $30,000 and $60,000 of administrative
support fees for the three and six months ended June 30, 2023, respectively. As of June 30, 2023 and December 31, 2022, we owed the Sponsor
$70,000 and $10,000, respectively, under this agreement, which is included in accounts payable and accrued expenses in the accompanying
condensed balance sheets. We began incurring these fees on August 9, 2021 and will continue to incur these fees monthly until the earlier
of the completion of the Business Combination and our liquidation.
In connection with our initial
business combination, we are obligated to pay our expenses relating thereto, including the deferred underwriting commissions payable to
our underwriter in an amount equal to 3.0% of the total gross proceeds raised in the offering, or $1,500,000, upon consummation of our
initial business combination.
Upon consummation of our IPO,
we sold to our underwriters, for $100, an option to purchase up to a total of 300,000 units (or up to 345,000 if the over-allotment is
exercised in full) exercisable, in whole or in part, at $11.50 per unit, commencing on the consummation of our initial business combination.
The purchase option may be exercised for cash or on a cashless basis, at the holder’s option, and expires five years from the commencement
of sales in our IPO. The option and the 300,000 units, as well as the 300,000 shares of common stock, and the warrants to purchase 300,000
shares of common stock that may be issued upon exercise of the option have been deemed compensation by FINRA and are therefore subject
to a lock-up for a period of 180 days immediately following the effective date of our registration statement, or August 9, 2021.
Critical Accounting Estimates
The preparation of financial
statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires
management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets
and liabilities at the date of the financial statements, and income and expenses during the periods reported. Actual results could materially
differ from those estimates. We have not identified any critical accounting estimates.
Recent Accounting Standards
Management does not believe
that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on our financial
statements.
ITEM 3. Quantitative and Qualitative Disclosures
About Market Risk
As a smaller reporting company,
we are not required to make disclosures under this Item.
ITEM 4. Controls and Procedures
Disclosure controls and procedures
are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted
under Securities Exchange Act of 1934, as amended (the “Exchange Act”) is recorded, processed, summarized and reported within
the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls
and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is
accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely
decisions regarding required disclosure.
Evaluation of Disclosure Controls and Procedures
Disclosure controls are procedures
that are designed with the objective of ensuring that information required to be disclosed in our reports filed under the Exchange Act,
such as this Report, is recorded, processed, summarized, and reported within the time period specified in the SEC’s rules and forms.
Disclosure controls are also designed with the objective of ensuring that such information is accumulated and communicated to our management,
including the chief executive officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure.
Our management evaluated, with the participation of our current chief executive officer and chief financial officer (our “Certifying
Officers”), the effectiveness of our disclosure controls and procedures as of June 30, 2023, pursuant to Rule 13a-15(b) under the
Exchange Act. Based upon that evaluation, our Certifying Officers concluded that, as of June 30, 2023, our disclosure controls and procedures
were not effective due to the material weakness identified as of December 31, 2022 and disclosed in our 2022 Form 10-K which continues
to exist as of June 30, 2023.
Our
management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f)
and 15d-15(f) of the Exchange Act). Under the supervision and with the participation of management, including the Chief Executive Officer
and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on
the criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the
Treadway Commission. Based on our evaluation under the framework in Internal Control - Integrated Framework, management concluded that
our internal control over financial reporting was not effective as of June 30, 2023 due to a material weakness in our financial close
process, specifically the classification of reinvestment of interest earned on marketable securities held in our Trust Account in the
statement of cash flows for the year ended December 31, 2022.
Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions,
or that the degree of compliance with the policies or procedures may deteriorate.
Remediation Plan
To
address this material weakness, management plans to provide processes and controls over the internal communications within the Company
and its financial advisors. We plan to include providing enhanced access to accounting literature, research materials and documents and
increased communication among our personnel and third-party professionals with whom we consult regarding accounting. The elements of our
remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended
effects.
Changes in Internal Control Over Financial
Reporting
Other than the remediation
plan discussed above, there were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f)
and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
ITEM 1. Legal Proceedings
None.
ITEM 1A. Risk Factors
As of the date of this Quarterly
Report on Form 10-Q, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K filed with the
SEC on March 30, 2023. Any of those risk factors could result in a significant or material adverse effect on our results of operations
or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business
or results of operations. We may disclose changes to such factors or disclose additional factors from time to time in our future filings
with the SEC.
ITEM 2. Unregistered Sales of Equity Securities
and Use of Proceeds
None.
ITEM 3. Defaults Upon Senior Securities
None.
ITEM 4. Mine Safety Disclosures
Not applicable.
ITEM 5. Other Information
None.
ITEM 6. Exhibits
The following exhibits are filed as part of, or
incorporated by reference into, this Quarterly Report:
| ** | Furnished
herewith. This certification is being furnished solely to accompany this report pursuant to 18 U.S.C. Section 1350 and is not being filed
for purposes of Section 18 of the Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filings of the
Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
ABRI SPAC I, INC. |
|
|
|
Date: August 14, 2023 |
By: |
/s/ Jeffrey Tirman |
|
|
Jeffrey Tirman |
|
|
Chief Executive Officer
(Principal Executive Officer) |
Date: August 14, 2023 |
By: |
/s/ Christopher Hardt |
|
|
Christopher Hardt |
|
|
Chief Financial Officer
(Principal Financial and Accounting
Officer) |
29
1252372
1252372
5733920
5733920
0.00
0.01
0.14
1728078
1728078
1728078
1728078
0.21
0.23
0.49
0.54
72023
72023
72023
72023
72023
0.01
0.23
0.00
0.21
0.00
0.49
0.14
0.54
false
--12-31
Q2
0001854583
0001854583
2023-01-01
2023-06-30
0001854583
aspa:UnitsEachConsistingOfOneShareOfCommonStockAndOneRedeemableWarrantMember
2023-01-01
2023-06-30
0001854583
aspa:CommonStockParValue00001PerShareMember
2023-01-01
2023-06-30
0001854583
aspa:WarrantsEachExercisableForOneShareOfCommonStockFor1150PerShareMember
2023-01-01
2023-06-30
0001854583
2023-08-14
0001854583
2023-06-30
0001854583
2022-12-31
0001854583
2023-04-01
2023-06-30
0001854583
2022-04-01
2022-06-30
0001854583
2022-01-01
2022-06-30
0001854583
aspa:RedemptionMember
2023-04-01
2023-06-30
0001854583
aspa:RedemptionMember
2022-04-01
2022-06-30
0001854583
aspa:RedemptionMember
2023-01-01
2023-06-30
0001854583
aspa:RedemptionMember
2022-01-01
2022-06-30
0001854583
aspa:NonredeemableMember
2023-04-01
2023-06-30
0001854583
aspa:NonredeemableMember
2022-04-01
2022-06-30
0001854583
aspa:NonredeemableMember
2023-01-01
2023-06-30
0001854583
aspa:NonredeemableMember
2022-01-01
2022-06-30
0001854583
us-gaap:CommonStockSubjectToMandatoryRedemptionMember
2022-12-31
0001854583
us-gaap:CommonStockMember
2022-12-31
0001854583
us-gaap:AdditionalPaidInCapitalMember
2022-12-31
0001854583
us-gaap:RetainedEarningsMember
2022-12-31
0001854583
us-gaap:CommonStockSubjectToMandatoryRedemptionMember
2023-01-01
2023-03-31
0001854583
us-gaap:CommonStockMember
2023-01-01
2023-03-31
0001854583
us-gaap:AdditionalPaidInCapitalMember
2023-01-01
2023-03-31
0001854583
us-gaap:RetainedEarningsMember
2023-01-01
2023-03-31
0001854583
2023-01-01
2023-03-31
0001854583
us-gaap:CommonStockSubjectToMandatoryRedemptionMember
2023-03-31
0001854583
us-gaap:CommonStockMember
2023-03-31
0001854583
us-gaap:AdditionalPaidInCapitalMember
2023-03-31
0001854583
us-gaap:RetainedEarningsMember
2023-03-31
0001854583
2023-03-31
0001854583
us-gaap:CommonStockSubjectToMandatoryRedemptionMember
2023-04-01
2023-06-30
0001854583
us-gaap:CommonStockMember
2023-04-01
2023-06-30
0001854583
us-gaap:AdditionalPaidInCapitalMember
2023-04-01
2023-06-30
0001854583
us-gaap:RetainedEarningsMember
2023-04-01
2023-06-30
0001854583
us-gaap:CommonStockSubjectToMandatoryRedemptionMember
2023-06-30
0001854583
us-gaap:CommonStockMember
2023-06-30
0001854583
us-gaap:RetainedEarningsMember
2023-06-30
0001854583
us-gaap:CommonStockSubjectToMandatoryRedemptionMember
2021-12-31
0001854583
us-gaap:CommonStockMember
2021-12-31
0001854583
us-gaap:AdditionalPaidInCapitalMember
2021-12-31
0001854583
us-gaap:RetainedEarningsMember
2021-12-31
0001854583
2021-12-31
0001854583
us-gaap:CommonStockSubjectToMandatoryRedemptionMember
2022-01-01
2022-03-31
0001854583
us-gaap:CommonStockMember
2022-01-01
2022-03-31
0001854583
us-gaap:AdditionalPaidInCapitalMember
2022-01-01
2022-03-31
0001854583
us-gaap:RetainedEarningsMember
2022-01-01
2022-03-31
0001854583
2022-01-01
2022-03-31
0001854583
us-gaap:CommonStockSubjectToMandatoryRedemptionMember
2022-03-31
0001854583
us-gaap:CommonStockMember
2022-03-31
0001854583
us-gaap:AdditionalPaidInCapitalMember
2022-03-31
0001854583
us-gaap:RetainedEarningsMember
2022-03-31
0001854583
2022-03-31
0001854583
us-gaap:CommonStockSubjectToMandatoryRedemptionMember
2022-04-01
2022-06-30
0001854583
us-gaap:CommonStockMember
2022-04-01
2022-06-30
0001854583
us-gaap:AdditionalPaidInCapitalMember
2022-04-01
2022-06-30
0001854583
us-gaap:RetainedEarningsMember
2022-04-01
2022-06-30
0001854583
us-gaap:CommonStockSubjectToMandatoryRedemptionMember
2022-06-30
0001854583
us-gaap:CommonStockMember
2022-06-30
0001854583
us-gaap:AdditionalPaidInCapitalMember
2022-06-30
0001854583
us-gaap:RetainedEarningsMember
2022-06-30
0001854583
2022-06-30
0001854583
us-gaap:IPOMember
2021-08-12
0001854583
us-gaap:IPOMember
2021-08-01
2021-08-12
0001854583
us-gaap:OverAllotmentOptionMember
2021-08-01
2021-08-23
0001854583
2021-08-01
2021-08-23
0001854583
2021-08-23
0001854583
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
2023-01-01
2023-06-30
0001854583
us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember
aspa:PrivateWarrantsMember
2023-06-30
0001854583
2022-08-05
0001854583
aspa:BusinessCombinationMember
2022-11-01
2022-11-01
0001854583
us-gaap:SubsequentEventMember
2023-08-12
0001854583
2023-02-06
0001854583
2023-03-10
0001854583
2023-04-11
0001854583
2023-05-11
0001854583
2023-06-09
0001854583
2023-07-10
0001854583
aspa:BusinessCombinationMember
2023-06-30
0001854583
aspa:TrustAccountRedemptionsMember
2023-03-10
0001854583
aspa:TrustAccountRedemptionsMember
2023-04-11
0001854583
aspa:TrustAccountRedemptionsMember
2023-05-11
0001854583
aspa:TrustAccountRedemptionsMember
2023-06-09
0001854583
aspa:TrustAccountRedemptionsMember
2023-07-10
0001854583
aspa:CommonSharesSubjectToRedemptionMember
2023-04-01
2023-06-30
0001854583
aspa:NonredeemableCommonSharesMember
2023-04-01
2023-06-30
0001854583
aspa:CommonSharesSubjectToRedemptionMember
2022-04-01
2022-06-30
0001854583
aspa:NonredeemableCommonSharesMember
2022-04-01
2022-06-30
0001854583
aspa:CommonSharesSubjectToRedemptionMember
2023-01-01
2023-06-30
0001854583
aspa:NonredeemableCommonSharesMember
2023-01-01
2023-06-30
0001854583
aspa:CommonSharesSubjectToRedemptionMember
2022-01-01
2022-06-30
0001854583
aspa:NonredeemableCommonSharesMember
2022-01-01
2022-06-30
0001854583
2022-11-01
0001854583
2023-02-10
0001854583
aspa:SponsorMember
2023-01-01
2023-06-30
0001854583
aspa:ConvertiblePromissoryNotesMember
2023-01-01
2023-06-30
0001854583
aspa:ConvertiblePromissoryNotesMember
2022-01-01
2022-12-31
0001854583
2022-01-01
2022-12-31
0001854583
aspa:FirstMilestoneEventMember
2023-06-30
0001854583
aspa:SecondMilestoneEventMember
2023-06-30
0001854583
aspa:ThirdMilestoneEventMember
2023-06-30
0001854583
us-gaap:OverAllotmentOptionMember
2023-01-01
2023-06-30
0001854583
2021-08-12
0001854583
aspa:CommonStockSubjectToRedemptionMember
2023-06-30
0001854583
aspa:CommonStockSubjectToRedemptionMember
2022-12-31
0001854583
us-gaap:IPOMember
2023-01-01
2023-06-30
0001854583
us-gaap:OverAllotmentOptionMember
2021-08-23
0001854583
aspa:BusinessCombinationMember
2023-01-01
2023-06-30
0001854583
aspa:BlackScholesPricingModelMember
2023-01-01
2023-06-30
0001854583
aspa:BlackScholesPricingModelMember
2023-06-30
0001854583
aspa:BlackScholesPricingModelMember
2023-04-01
2023-06-30
0001854583
aspa:WarrantLiabilitiesMember
2022-12-31
0001854583
aspa:WarrantLiabilitiesMember
2023-01-01
2023-03-31
0001854583
aspa:WarrantLiabilitiesMember
2023-03-31
0001854583
aspa:WarrantLiabilitiesMember
2023-04-01
2023-06-30
0001854583
aspa:WarrantLiabilitiesMember
2023-06-30
0001854583
aspa:WarrantLiabilitiesMember
2021-12-31
0001854583
aspa:WarrantLiabilitiesMember
2022-01-01
2022-03-31
0001854583
aspa:WarrantLiabilitiesMember
2022-03-31
0001854583
aspa:WarrantLiabilitiesMember
2022-04-01
2022-06-30
0001854583
aspa:WarrantLiabilitiesMember
2022-06-30
0001854583
us-gaap:FairValueInputsLevel1Member
2023-06-30
0001854583
us-gaap:FairValueInputsLevel2Member
2023-06-30
0001854583
us-gaap:FairValueInputsLevel3Member
2023-06-30
0001854583
us-gaap:FairValueInputsLevel1Member
2022-12-31
0001854583
us-gaap:FairValueInputsLevel2Member
2022-12-31
0001854583
us-gaap:FairValueInputsLevel3Member
2022-12-31
0001854583
2022-08-16
2022-08-16
0001854583
aspa:SponsorMember
us-gaap:SubsequentEventMember
2023-07-11
0001854583
us-gaap:SubsequentEventMember
2023-07-11
0001854583
aspa:SponsorMember
us-gaap:SubsequentEventMember
2023-07-31
0001854583
us-gaap:SubsequentEventMember
2023-07-31
0001854583
aspa:SponsorMember
us-gaap:SubsequentEventMember
2023-07-10
0001854583
us-gaap:SubsequentEventMember
2023-08-07
2023-08-07
0001854583
us-gaap:SubsequentEventMember
2023-08-07
xbrli:shares
iso4217:USD
iso4217:USD
xbrli:shares
xbrli:pure
In connection with the Quarterly Report of Abri
SPAC I, Inc. (the “Company”) on Form 10-Q for the period ended June 30, 2023 as filed with the Securities and Exchange Commission
(the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that: